Table I.
Recombinant Ebola virus subunits protect mice against live virus challenge
| Group no. | Immunogena | Adjuvant | Survival (day 20 post challenge) | P value vs. adjuvant control groupb |
|---|---|---|---|---|
| 1 | GP | NONE | 7/10c | 0.0015 |
| 2 | GP | GPI-0100 | 9/10c | 0.0005 |
| 3 | GP | CoVaccine HT™ | 10/00 | <0.0001 |
| 4 | VP24 | NONE | 0/10 | >0.05 |
| 5 | VP24 | GPI-0100 | 0/10 | >0.05 |
| 6 | VP24 | CoVaccine HT™ | 6/10c | 0.0054 |
| 7 | VP40 | NONE | 0/10 | >0.05 |
| 8 | VP40 | GPI-0100 | 0/10 | >0.05 |
| 9 | VP40 | CoVaccine HT™ | 0/10 | >0.05 |
| 10 | GP + VP40 + VP24 | NONE | 9/10 | <0.0001 |
| 11 | GP + VP40 + VP24 | GPI-0100 | 10/10 | <0.0001 |
| 12 | GP + VP40 + VP24 | CoVaccine HT™ | 10/10 | <0.0001 |
| 13 | NONE | NONE | 0/9 | --- |
| 14 | NONE | GPI-0100 | 1/10c | --- |
| 15 | NONE | CoVaccine HT™ | 0/10% | --- |
a
Mice were immunized with 10 μg of each antigen by the i.m. route.
b
Adjuvant control groups: 13 (no adjuvant), 14 (GPI-0100), 15 (CoVaccine HT™)
c
Animals showed signs of illness for part of the study(e.g. ruffled fur).